Table 2.

Adjusted associations of plasma miRNAs with treatment failure in TODAY miRNA study participants (N = 209)

	Model 1: miR-4306 only			Model 2: miR-483-3p only			Model 3: miR-4306 and miR-483-3p
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
HbA1c	2.91	1.98, 4.28	<0.001	2.71	1.87, 3.93	<0.001	2.97	2.01, 4.39	<0.001
Tanner stage 4–5	1.21	0.58, 2.53	0.610	1.10	0.51, 2.34	0.810	1.05	0.49, 2.26	0.910
Latinx ethnicity*	1.11	0.68, 1.84	0.670	0.95	0.57, 1.61	0.860	1.00	0.59, 1.68	0.980
White race*	0.47	0.23, 0.96	0.040	0.42	0.21, 0.86	0.020	0.44	0.22, 0.91	0.030
Other race*	0.89	0.26, 3.09	0.850	1.00	0.29, 3.47	1.000	0.92	0.27, 3.21	0.900
BMI z score	0.81	0.64, 1.03	0.090	0.77	0.61, 0.99	0.040	0.79	0.62, 1.01	0.060
Female sex	1.15	0.71, 1.86	0.560	1.15	0.71, 1.86	0.560	1.13	0.70, 1.83	0.620
Maternal history of diabetes	1.51	0.93, 2.47	0.100	1.72	1.04, 2.82	0.030	1.60	0.97, 2.63	0.060
Log-transformed C-peptide oral disposition index	0.56	0.4, 0.79	0.001	0.56	0.4, 0.79	0.001	0.59	0.42, 0.83	0.003
Randomly assigned to rosiglitazone	0.55	0.3, 0.99	0.050	0.56	0.31, 1.03	0.060	0.57	0.31, 1.03	0.070
Randomly assigned to lifestyle	1.42	0.81, 2.46	0.220	1.34	0.77, 2.36	0.300	1.33	0.76, 2.32	0.310
miR-4306	0.88	0.78, 1.00	0.040				0.89	0.78, 1.01	0.070
miR-483-3p				1.12	0.99, 1.28	0.080	1.07	0.97, 1.26	0.120

HR, hazard ratio.

^*Compared with non-Hispanic Black race.